---
title: "Cathay Biotech: 2024 net profit is expected to grow by 33.41% year-on-year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/236809596.md"
description: "Cathay Biotech announced that the operating revenue for 2024 is expected to be 2.958 billion yuan, a year-on-year increase of 39.91%. The net profit attributable to shareholders of the listed company is expected to be 489 million yuan, a year-on-year increase of 33.41%. It is proposed to distribute a cash dividend of 4 yuan for every 10 shares to all shareholders"
datetime: "2025-04-21T13:58:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/236809596.md)
  - [en](https://longbridge.com/en/news/236809596.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/236809596.md)
generator: "portal-rs"
---

# Cathay Biotech: 2024 net profit is expected to grow by 33.41% year-on-year

Cathay Biotech announced that the operating revenue for 2024 is expected to be 2.958 billion yuan, a year-on-year increase of 39.91%. The net profit attributable to shareholders of the listed company is expected to be 489 million yuan, a year-on-year increase of 33.41%. It is proposed to distribute a cash dividend of 4 yuan for every 10 shares to all shareholders

### Related Stocks

- [688065.CN](https://longbridge.com/en/quote/688065.CN.md)

## Related News & Research

- [REG - Cadence Minerals PLC - Azteca Cold and Wet Commissioning Underway](https://longbridge.com/en/news/298909508.md)
- [Havas, linked to Louis Hachette director Yannick Bolloré, purchases EUR 5.31 million of Louis Hachette Group shares](https://longbridge.com/en/news/298621675.md)
- [Saeed Zarrouk Leads Preparations for Potential Long-Term DAZN Bid to Bring CAF Competitions to a Global Audience](https://longbridge.com/en/news/298757088.md)
- [Atrys Health Accelerates Growth and Slashes Debt in First Half of 2026](https://longbridge.com/en/news/298692631.md)
- [ABEC to expand global manufacturing network with new Wilson facility](https://longbridge.com/en/news/298710451.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**